| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Here's a roundup of top developments in the biotech space over the last 24 hours:
(Biotech Stocks Hitting 52-week Highs Dec. 10)
(Biotech Stocks Hitting 52-week Lows Dec. 10)
Pfizer Inc. (NYSE:PFE) and BioNTech SE – ADR (NASDAQ:BNTX) said the FDA's Vaccines and Related Biological Products Advisory Committee voted 17 to 4 in support of the FDA granting emergency use authorization for the companies' COVID-19 mRNA vaccine, BNT162b2.
Pfizer shares added 2.76% to $42.88 in after-hours trading and BioNTech advanced 3.44% to $134.
Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE:BIO) announced 2023 guidance, expecting sales of $2.75 billion-$2.85 billion and a non-GAAP adjusted EBITDA margin of 23%-24%. The company sees sales getting a lift from its broad portfolio of products including Droplet Digital PCR, single-cell, clinical diagnostics and a focus on the bioproduction and biopharma channels.
Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) announced an agreement with Crown Laboratories, a skin care company, for the exclusive rights to sell and market Sonoma's products for the over-the-counter dermatological market in the U.S.
Under the agreement, Crown will sell Sonoma's Microcyn technology dermal sprays and gels targeting itch and pain under the Sarna brand, with a unique variety of formulations to quickly relieve itch and skin irritations.
The stock was up 116.13% at $13.40 premarket Friday.
Dynavax Technologies Corporation (NASDAQ:DVAX) said the European Medicines Agency's Committee For Medicinal Products For Human Use has issued a positive opinion on its marketing authorization application, recommending the granting of marketing authorization for the Heplisav-B vaccine.
The vaccine is for active immunization against hepatitis B virus infection caused by all known subtypes of hepatitis B virus in adults 18 and older.
Dynavax shares were up 3.06% at $4.71 premarket.
Passage Bio Inc (NASDAQ:PASG) said the U.K. Medicines Healthcare Products Regulatory Agency has approved the clinical trial authorization for PBGM01, its lead gene therapy candidate being studied for the treatment of GM1 gangliosidosis.
Patient enrollment for the UK clinical study site, which is part of the global program, is expected to start in the second quarter of 2021, the company said.
In after-hours trading, the stock rose 4.09% to $28.99.
Innate Pharma SA (NASDAQ:IPHA) said it will return the U.S. and EU commercialization rights of Lumoxiti, which it acquired from AstraZeneca plc (NASDAQ:AZN) in October 2018. Lumoxiti was approved by the FDA in 2018 to treat patients with relapsed and refractory hairy cell leukemia.
The U.S. rights will be transferred to AstraZeneca in 2021, with the company also remaining the marketing authorization applicant for the EU filing.
Innate also said it will immediately begin to reduce its U.S. commercial operations.
Roche Holdings AG Basel ADR Common Stock (OTC:RHHBY) said it has launched a high-throughput SARS-CoV-2 antigen test to diagnose SARS-CoV-2 infections in markets accepting the CE Mark. The company said it has also filed for emergency use authorization from the FDA.
Sanofi SA (NASDAQ:SNY) and GlaxoSmithKline plc (NYSE:GSK) announced a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in older adults.
The Phase 1/2 study interim results showed an immune response comparable to patients who recovered from COVID-19 in adults ages 18-49, but a low immune response in older adults, likely due to an insufficient concentration of the antigen, the companies said.
The companies based the decision on the results from a recent challenge study in non-human primates performed with an improved antigen formulation, which demonstrated that the vaccine candidate could protect against lung pathology and lead to rapid viral clearance from the nasal passages and lungs within two to four days.
Sanofi and GSK now plan to start a Phase 2b study in February 2021, with the study including a proposed comparison with an authorized COVID-19 vaccine. If the data is positive, a global Phase 3 study could start in the second quarter of 2021 and regulatory submissions could be made in the second half of 2021. The vaccine's potential availability is therefore delayed from mid-2021 to the fourth quarter of 2021.
Xeris Pharmaceuticals Inc (NASDAQ:XERS) said the EMA's CHMP has adopted a positive opinion for Ogluo, its RTU glucagon for injection. The CHMP recommends Ogluo for the treatment of severe hypoglycemia in adults, adolescents and children ages 2 years and older with diabetes mellitus.
If approved, the company said Ogluo could be launched in certain European countries in the second half of 2021.
In premarket trading Friday, the stock was up 6.6% to $4.36.
Nabriva Therapeutics PLC – ADR (NASDAQ:NBRV) priced its public offering of 6 million ordinary shares, or pre-funded warrants in lieu thereof, at an effective price of $2.50 per share or pre-funded warrant.
The gross proceeds to Nabriva Therapeutics from the offering are expected to be $15 million. The offering is expected to close on or about Dec. 15.
The stock was down 29.71% premarket at $2.39.
Aytu BioScience (NASDAQ:AYTU) announced an increase in the size of its previously announced public offering and purchase on a firm commitment basis to 4.17 million shares, with the offering priced at $6 per share. The closing of the offering is expected to occur on or about Dec. 15.
9 Meters Biopharma Inc (NASDAQ:NMTR) said it has commenced a proposed underwritten public offering of shares of its common stock. All of the shares in the proposed offering are to be sold by the company.
The stock slipped 9.4% to 77 cents in after-hours trading.
Opiant Pharmaceuticals Inc (NASDAQ:OPN) said it has entered into a $50-million convertible note purchase and security agreement with a syndicate of Pontifax Medison Finance, a health care-dedicated venture and debt fund, and European growth debt firm Kreos Capital.
The company said it expects to use the proceeds to fund the potential future commercialization of OPNT003, nasal nalmefene, an investigational treatment for opioid overdose, which it aims to file for approval by the FDA at the end of 2021.
The stock fell 1.93% to $8.15 in after-hours trading.
Odonate Therapeutics Inc (NASDAQ:ODT) will present at the San Antonio Breast Cancer Symposium with the results of CONTESSA, a Phase 3 study of tesetaxel in the treatment of patients with metastatic breast cancer.
Sellas Life Sciences Group Inc (NASDAQ:SLS) Is scheduled to present at the SABCS with finalized data from the Phase 2 study of nelipepimut-S in combination with granulocyte-macrophage colony-stimulating factor in women with ductal carcinoma in situ of the breast who are HLA-A2+ or A3+ positive, express HER2 at IHC 1+, 2+ or 3+ levels, and are pre- or post-menopausal.
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, priced its initial public offering of 8.4 million shares of its common stock at a price of $23 per share, for raising gross proceeds of $193.2 million.
All of the shares are being offered by the company. The shares are expected to begin trading on the Nasdaq under the ticker symbol "FDMT."
Certara, a biosimulation company, priced its upsized IPO of 29.055 million shares at $23 per share. Shares of Certara will begin trading on the Nasdaq under the ticker symbol "CERT." The gross proceeds from the offering will be about $336.5 million.
Abcellera Biologics, a technology company that searches, decodes and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease, priced its IPO of 24.15 million common shares at $20 per share. All of the common shares are being offered by AbCellera. The shares of the company are expected to begin trading on the Nasdaq under the ticker symbol "ABCL." The gross proceeds from the offering are expected to be $483 million.
Vivos Therapeutics, a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, priced its IPO of 3.5 million shares of its common stock at a $6 per share. The shares of common stock are expected to begin trading on the Nasdaq under the ticker "VVOS."
Related Link: Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
Posted In: ADPT ALXO ANIX ARWR AYTU AZN BASI BBIO BEAM BEAT BIO BLCM BLFS BNTX BPMC CDNA CMPI CORT CRIS CSTL
